PISCATAWAY, NJ -- (Marketwired) -- 04/23/13 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it has concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the Company, and that ...
Wilmington, DE -- (SBWIRE) -- 04/24/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Tranzyme, Inc. (NASDAQ:TZYM), Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), and Amgen Inc. (NASDAQ:AMGN). Tranzyme, Inc.
Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) declined 11.20% to $3.40 on a traded volume of 191k shares. Enzon Pharmaceuticals, Inc. has concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the ...
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) shares dropped 11.23% to $3.40. The company on April 23 announced that it has concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the Company, and ...
Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) traded at $4.05, up 5.7 percent during After-Hours on 2,400 share volume. The company traded -7.50 percent below its 50-day moving average and -16.84 percent below its 200-day moving average.
During the period, Baupost reduced its stockholdings in the following companies: Enzon Pharmaceuticals Inc (NASDAQ:ENZN) by 158,918 shares, Alliance One international Inc (NYSE:AOI) by 655,106 shares, Ituran Location & Control Ltd (NASDAQ:ITRN) ...
Enzon Pharmaceuticals, Inc. is engaged in developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions.
Enzon Pharmaceuticals Inc(NASDAQ:ENZN) finished last trading day, -11.23% lower to move at $3.40 after concluded review of possible asset sale, sale of company and declared special dividend of $1.60 per share.
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. To see all exchange delays, please see disclaimer.